bioRxiv · 10.1101/2025.05.06.652559
AI-powered integration of multi-source data for TAA discovery to accelerate ADC and TCE drug development (I): TAA Target Identification and Prioritization
Abstract
The advancement of T-cell engagers (TCEs) and antibody-drug conjugates (ADCs) has been hindered by fragmented data landscapes. This paper, the first in a series, introduces an AI-driven framework specifically for tumor-associated antigen (TAA) target identification and prioritization, a critical initial step in TCE and ADC development. Our framework integrates diverse datasets-- including multi-omics repositories and information from scientific publications--to systematically enhance the discovery of TAAs. We have developed a graph retrieval-augmented generation (RAG)-enhanced language model that extracts insights from biological and clinical literature, while integrating curated public oncology-related omics databases such as TCGA, GTEx, single-cell atlases, and additional omics datasets. This approach prioritizes TAAs with high tumor selectivity and low on-target/off-tumor risk. By unifying diverse knowledge sources, our method provides a scalable, efficient, and data-agnostic strategy to address attrition challenges in both ADC and TCE drug development pipelines, focusing initially on TAA target identification and prioritization to transform the landscape of cancer therapeutics.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Xie, T., Huang, C.-H.. 2025-05-08. AI-powered integration of multi-source data for TAA discovery to accelerate ADC and TCE drug development (I): TAA Target Identification and Prioritization. https://doi.org/10.1101/2025.05.06.652559
Cite the original work for its findings. Save a collection to share your selection of sources.